Shopping Cart
- Remove All
Your shopping cart is currently empty
YHO-13351 free base
🥰Excellent
Catalog No. T13365Cas No. 912288-64-3
YHO-13351 free base, the water-soluble prodrug of YHO-13177, is an inhibitor of BCRP (breast cancer resistance protein).
YHO-13351 free base
🥰Excellent
Purity: 100%
Catalog No. T13365Cas No. 912288-64-3
YHO-13351 free base, the water-soluble prodrug of YHO-13177, is an inhibitor of BCRP (breast cancer resistance protein).
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | 28 € | In Stock | |
| 5 mg | 60 € | In Stock | |
| 10 mg | 100 € | In Stock | |
| 25 mg | 186 € | In Stock | |
| 50 mg | 297 € | In Stock | |
| 100 mg | 455 € | In Stock | |
| 500 mg | 997 € | In Stock | |
| 1 mL x 10 mM (in DMSO) | 67 € | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "YHO-13351 free base"
Elacridar
GW120918, GW0918, GG918, GF120918
T2657143664-11-3
Elacridar (GG918) is a potent inhibitor of P-glycoprotein and BCRP.
- 33 €
Size
QTY
GS-9191 PM
T67821In house
GS-9191 PM is a novel antitumorviral compound, a bis-amide prodrug of the nucleotide analog 9-(2-phosphonomethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine (cPrPMEDAP).GS-9191 PM is a potent inhibitor of MDR1 and BCRP.GS-9191 PM exhibits both antiproliferative and antitumorviral activities.
- 131 €
Size
QTY
KS176
T35811253452-78-6
KS176 is a potent and selective inhibitor of the breast cancer resistance protein (BCRP) multidrug transporter, exhibiting no inhibitory activity against P-gp or MRP1.
- 27 €
Size
QTY
Triclabendazole sulfoxide
TCBZ-SO
T38400100648-13-3
Triclabendazole sulfoxide (TCBZ-SO), a primary plasma metabolite of Triclabendazole, inhibits the membrane transporter ABCG2/BCRP and demonstrates anti-parasite effects.
- 42 €
Size
QTY
Zamicastat
BIA 5-1058
T133831080028-80-3
Zamicastat (BIA 5-1058) is an inhibitor of dopamine β-hydroxylase (DBH) and a concentration-dependent dual inhibitor of P-gp and BCRP, with IC50 values of 73.8 μM and 17.0 μM, respectively.
- 83 €
Size
QTY
YHO-13177
YHO13177, YHO 13177
T4595912287-56-0
YHO-13177 is a potent and specific inhibitor of BCRP, which enhances the cytotoxicity of SN-38 in cancer cells without affecting P-glycoprotein–mediated paclitaxel resistance in [MDR1]-transduced human leukemia [K562] cells.
- 31 €
Size
QTY
PCI 29732
PCI-29732, PCI29732
T4337330786-25-9
PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.
- 32 €
Size
QTY
Ko 143
TQ0186461054-93-3
Ko 143 is a selective inhibitor of ATP-binding cassette sub-family G member 2 (ABCG2; BCRP).
- 37 €
Size
QTY
Brevianamide F
Cyclo-L-tryptophyl-L-proline, cyclo-(L-Trp-L-Pro), Cyclo(L-Pro-L-Trp)
T320838136-70-8
Brevianamide F (Cyclo(L-Pro-L-Trp)), also known as cyclo-(L-Trp-L-Pro), is a naturally occurring 2,5-diketopiperazine with notable breast cancer resistance protein inhibitory activity.
- 35 €
Size
QTY
CP-100356 hydrochloride
CP-100356 HCl, CP 100356 hydrochloride
T22680142715-48-8
CP-100356 hydrochloride is an orally active, low micromolar dual inhibitor of MDR1 (P-gp) and BCRP, a nucleotide-derived substrate analogue that inhibits MDR1-mediated Calcein-AM and BCRP-mediated Prazosin transporters. Additionally, CP-100356 inhibits OATP1B1 and induces stomatal opening in the dark.
- 65 €
Size
QTY
6,8-Diprenylnaringenin
Senegalensin, Lonchocarpol A
TN315068236-11-3
6,8-Diprenylnaringenin (Senegalensin) is a natural product from hop Humulus lupulus. 6,8-Diprenylnaringenin is a breast cancer resistance protein(BCRP) inhibitor with some estrogenicity.
- 396 €
Size
QTY
LRRK2-IN-15
T200475
LRRK2-IN-15 is an inhibitor of LRRK2. It exhibits an IC50 value of 5 nM in PBMC cells and 1.5 μM for BCRP. This compound is utilized in the research of Parkinson's disease.
- Inquiry Price
Size
QTY
Select Batch
Purity:100%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | YHO-13351 free base, the water-soluble prodrug of YHO-13177, is an inhibitor of BCRP (breast cancer resistance protein). |
| In vivo | In mice, YHO-13351 was rapidly converted into YHO-13177 after its oral or intravenous administration. Coadministration of Irinotecan Hydrochloride with YHO-13351 significantly increased the survival time of mice inoculated with BCRP-transduced murine leukemia P388 cells and suppressed the tumor growth in an HCT116/BCRP xenograft model, whereas Irinotecan Hydrochloride alone had little effect in these tumor models[1]. |
| Molecular Weight | 483.62 |
| Formula | C26H33N3O4S |
| Cas No. | 912288-64-3 |
| Smiles | CCN(CC)CC(=O)OC1CCN(CC1)c1ccc(\C=C(/C#N)c2ccc(OC)c(OC)c2)s1 |
| Relative Density. | 1.22 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 90 mg/mL (186.1 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy YHO-13351 free base | purchase YHO-13351 free base | YHO-13351 free base cost | order YHO-13351 free base | YHO-13351 free base chemical structure | YHO-13351 free base in vivo | YHO-13351 free base formula | YHO-13351 free base molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.